A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial
A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
Inclusion criteria:
Group A (Bleeding patients)
Group B (Patients who are taking dabigatran who may not be bleeding, but do require an emergency surgery or procedure for a condition other than bleeding
Exclusion criteria:
Group A (Bleeding Patients)
Group B (Patients who require emergency surgery or procedure)
Wilton, Ireland
Aichi, Nagoya, 466-8650, Japan
Fukuoka, Kasuga, 816-0864, Japan
Gifu, Ogaki, 503-8502, Japan
Hyogo, Nishinomiya, 663-8501, Japan
Kagoshima, Kagoshima, 892-0853, Japan
Kanagawa, Kamakura, 247-8533, Japan
Osaka, Suita, 565-8565, Japan
Tokyo, Bunkyo-Ku, 113-8603, Japan
Tokyo, Tachikawa, 190-0014, Japan
Yamagata, Yamagata, 990-8533, Japan
Grafton / Auckland, 1023, New Zealand
Otahuhu South Auckland, 2025, New Zealand
Takapuna Auckland, 0620, New Zealand